en · de · es · fr · pt
tb-500-notes.peptides9002.com › Data › Identity And Reported Background — Research Overview

Identity And Reported Background — Research Overview

By Editorial Desk · published 2026-01-28 · last reviewed 2026-02-18 · Data

The short version of thymosin beta-4 fragment fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-02-18. Anything still debated is marked as such rather than presented as settled.

Identity and Reported Background

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.

TB-500 Background and Identity

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Tb-500 at a glance

PropertyValueNotes
Reported sequenceAc-LKKTETQDescribed in most listings as the actin-binding region of thymosin beta-4
Reported molecular weightApproximately 889 DaValue shifts with the stated sequence; compare against the certificate of analysis
Parent protein length43 amino acidsThymosin beta-4; the fragment covers only a small part of it
Common synonymsTB4 fragment; thymosin beta-4 fragmentTrade-style names rather than formal nomenclature
Formal monographsNot establishedLabeling conventions differ by supplier and region

Handling, Stability and Analytical Detection

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Related pages on this site

Identity and Research Background

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Background from the literature

Although there was an improvement in insulin resistance and serum aminotransferases, this did not translate into MASH improvements. The NICE provides similar guidelines to the AASLD regarding pioglitazone and recommends it be administered in secondary care to adults with advanced liver fibrosis irrespective of whether or not they have diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1s) are at least as effective as pioglitazone and Vitamin E and significantly reduce steatosis, ballooning necrosis, lobular inflammation, and fibrosis according to a 2023 systematic review. Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists appear to be effective treatments; tirzepatide was more effective than placebo for resolution of MASH without worsening of fibrosis in patients with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis when given once-weekly for 52 weeks, while survodutide decreased liver fat content and improved fibrosis compared to placebo (32% of people had MASH resolution or at least 1 level of improvement in their fibrosis scores), although with more frequent adverse effects of nausea, diarrhea, and vomiting SGLT-2 inhibitors were associated with MASH resolution in 23% of people, reduced liver fat content on non-invasive testing (MRI), and a 45% reduction in fibrosis after 24 weeks of therapy. Long-term use of SGLT-2 inhibitors may also be associated with a lower risk of liver-related complications and death from liver disease as compared to GLP-1 receptor agonists.

In particular, in the Born–Oppenheimer and harmonic approximations (i.e. when the molecular Hamiltonian corresponding to the electronic ground state can be approximated by a harmonic oscillator in the neighbourhood of the equilibrium molecular geometry), the resonant frequencies are associated with the normal modes of vibration corresponding to the molecular electronic ground state potential energy surface. Thus, it depends on both the nature of the bonds and the mass of the atoms that are involved. Using the Schrödinger equation leads to the selection rule for the vibrational quantum number in the system undergoing vibrational changes:

== Early life and career == An Israeli-American, Ashkenazi earned a degree in finance and economics from the Hebrew University of Jerusalem and an MBA from Tel Aviv University. She worked in the financial services sector in Israel, including for Ma'alot Standard & Poor's and Bank Hapoalim.

IUPAC and UNESCO were the lead organizations coordinating events for the International Year of Chemistry, which took place in 2011. The International Year of Chemistry was originally proposed by IUPAC at the general assembly in Turin, Italy. This motion was adopted by UNESCO at a meeting in 2008. The main objectives of the International Year of Chemistry were to increase public appreciation of chemistry and gain more interest in the world of chemistry. This event is also being held to encourage young people to get involved and contribute to chemistry. A further reason for this event being held is to honour how chemistry has made improvements to everyone's way of life.

Sources: en.wikipedia.org

Reference notes

fluid mosaic model The prevailing scientific model of the structure and properties of cell membranes, according to which the typical membrane consists of back-to-back layers of amphipathic membrane lipids (generally phospholipids or glycolipids) interspersed with a dynamic variety of embedded proteins, carbohydrates, and (especially in animal cells) cholesterol, all of which behave as if suspended in a "two-dimensional liquid", constantly moving laterally between the lipids and interacting with each other and with the cytoplasm and the extracellular space. The membrane as a whole thus retains a fluidity and elasticity which allow it to change shape and adapt to the cell's environment.

Sidney Walter Fox (24 March 1912 – 10 August 1998) was a Los Angeles-born biochemist responsible for discoveries on the origins of biological systems. Fox explored the synthesis of amino acids from inorganic molecules, the synthesis of proteinous amino acids and amino acid polymers called "proteinoids" from inorganic molecules and thermal energy, and created what he thought was the world's first protocell out of proteinoids and water. He called these globules "microspheres". Fox believed in the process of abiogenesis where life spontaneously organized itself from the colloquially known "primordial soup;" poolings of various simple organic molecules that existed during the time before life on Earth. He also suggested that his experiments possessed conditions that were similar to those of primordial Earth. In his experiments, Fox demonstrated that it is possible to create protein-like structures from inorganic molecules and thermal energy. Fox went on to create microspheres that he said closely resembled bacterial cells and concluded that they could be similar to the earliest forms of life or protocells.

In a solid, shear stress is a function of strain, but in a fluid, shear stress is a function of strain rate. A consequence of this behavior is Pascal's law which describes the role of pressure in characterizing a fluid's state. The behavior of fluids can be described by the Navier–Stokes equations—a set of partial differential equations which are based on:

Sources: en.wikipedia.org

Reference notes

However, after Owen Hart accidentally injured Austin's neck in 1997, Austin changed his style from technical to brawler. His most famous finishing move is the Stone Cold Stunner, and he credits Michael Hayes with introducing the move to him. Following his retirement, he gave permission to Kevin Owens to use the move as his own finisher, but both have downplayed comparisons between the two. During his time as The Ringmaster, he used the Million Dollar Dream as a finishing move since it was Ted DiBiase's finisher. During his time in WCW, Austin used the Stun Gun (a move innovated by Eddie Gilbert as the Hot Shot) and the Hollywood & Vine (a standing modified figure-four leglock) as his finishers. Sporting a bald head and goatee, coupled with his ring attire which consisted of plain black trunks and boots, Austin relied solely on his personality to become popular. As "Stone Cold", Austin was portrayed on-screen as an anti-authority rebel who would consistently cuss and defy the company rules and guidelines of WWE Chairman Vince McMahon. One of Austin's taunts during the Attitude Era was to show the middle finger. To complement his persona, Austin was the recipient of two additional nicknames, commentator and real life friend Jim Ross dubbed him "The Texas Rattlesnake" due to the character's "...mannerisms, the motivation, the mindset, you can't trust this son of a bitch", while Austin later named himself "The Bionic Redneck" on account of the injuries he had suffered to his arms, neck and knees.

The Inca roads were used to transport food, goods, people, and armies, while Inca officials frequently relayed messages using the roads across the vast stretches of the Inca Empire. In areas, where rivers blocked the directions of the roads, the Inca constructed elaborate and complex rope bridges.

=== Benzene toxicity === Benzene poisoning can increase risk of hematological cancers and other disorders. The mechanism of benzene metabolism and how it affects toxicity has not been completely understood. A general observation is that there is high variation in the extent of damage due to benzene poisoning. A possible explanation is the accumulation of phenols and hydroquinone in the target organ—the bone marrow—and subsequent oxidation of these metabolites to reactive quinone metabolites via a number of possible pathways. A case-control study conducted in China showed that patients with two copies of the NQO1 C609T (NQO1*2 polymorphism) mutation had a 7.6-fold increased risk of benzene poisoning compared to those who carried one or two wild-type NQO1 alleles.

When the protein is labelled with carbon-13 and nitrogen-15 it is possible to record triple resonance experiments that transfer magnetisation over the peptide bond, and thus connect different spin systems through bonds. This is usually done using some of the following experiments, HNCO, HN(CA)CO}, HNCA, HN(CO)CA, HNCACB and CBCA(CO)NH. All six experiments consist of a 1H-15N plane (similar to a HSQC spectrum) expanded with a carbon dimension. In the HN(CA)CO, each HN plane contains the peaks from the carbonyl carbon from its residue as well the preceding one in the sequence. The HNCO contains the carbonyl carbon chemical shift from only the preceding residue, but is much more sensitive than HN(CA)CO. These experiments allow each 1H-15N peak to be linked to the preceding carbonyl carbon, and sequential assignment can then be undertaken by matching the shifts of each spin system's own and previous carbons. The HNCA and HN(CO)CA works similarly, just with the alpha carbons (Cα) rather than the carbonyls, and the HNCACB and the CBCA(CO)NH contains both the alpha carbon and the beta carbon (Cβ). Usually several of these experiments are required to resolve overlap in the carbon dimension. This procedure is usually less ambiguous than the NOESY-based method since it is based on through bond transfer. In the NOESY-based methods, additional peaks corresponding to atoms that are close in space but that do not belong to sequential residues will appear, confusing the assignment process.

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 made of?

Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.

Why do product descriptions differ between suppliers?

Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Network